BRAF and Charlevoix-Saguenay spastic ataxia: Similarly, to TNBC, SAC cases are mainly resistant to molecular targeted therapy such as anti-EGFR and immune checkpoint inhibitors as most SACs carry KRAS or BRAF mutation and are microsatellite stable (7, 8, 31).